AKT1 and neoplasm: Although the combination of immunotherapies and PI3K-AKT pathway inhibitors elicits partially effective to reinvigorate tumor-infiltrating T cells26, the immunosuppressive tumor environment can hardly be transformed, which suggests that other signaling pathways are also triggered in addition to PTEN dysfunction.